Novartis forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.

Pfizer announced a second collaboration agreement with Arvinas to develop and commercialize the Connecticut-based company’s PROTAC estrogen receptor protein degrader.

Roivant Sciences, the umbrella company for Vivek Ramaswamy’s series of ‘vant companies, acquired Silicon Therapeutics for $450 million in Roivant equity.